Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Return on Equity (2016 - 2025)

Voyager Therapeutics' Return on Equity history spans 11 years, with the latest figure at 0.58% for Q4 2025.

  • For Q4 2025, Return on Equity fell 37.0% year-over-year to 0.58%; the TTM value through Dec 2025 reached 0.58%, down 37.0%, while the annual FY2025 figure was 0.48%, 24.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.58% at Voyager Therapeutics, down from 0.55% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.72% in Q1 2023 and bottomed at 1.04% in Q3 2021.
  • The 5-year median for Return on Equity is 0.23% (2022), against an average of 0.2%.
  • The largest annual shift saw Return on Equity tumbled -137bps in 2021 before it soared 153bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.81% in 2021, then rose by 18bps to 0.67% in 2022, then skyrocketed by 196bps to 0.64% in 2023, then tumbled by -132bps to 0.21% in 2024, then tumbled by -179bps to 0.58% in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Return on Equity are 0.58% (Q4 2025), 0.55% (Q3 2025), and 0.42% (Q2 2025).